ESOPHAGEAL ADENOCARCINOMA

This study tests whether a new drug called zanidatamab, given with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for people with advanced HER2-positive stomach or esophageal cancer that has spread or cannot be removed by …

This study tested whether using a person's genetic information to adjust the dose of a chemotherapy drug (irinotecan) could help patients with advanced stomach or esophageal cancer. The goal was to see if this personalized approach could make surgery more successful by shrinking …

This study tests whether adding two immunotherapy drugs, durvalumab and tremelimumab, to standard chemoradiation is safe and effective for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination after initial chemotherapy. Th…

This study tests a new combination of drugs (futibatinib plus standard immunotherapy) in adults with advanced esophageal or pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors and is safe. About 53 people will take part, and t…

This study is testing whether a drug called tucatinib can be safely combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) to treat HER2-positive cancers of the digestive system. About 40 adults with advanced stomach, bowel, or gallbladder cancer are …

This study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with locally advanced esophageal adenocarcinoma. About 42 adults whose cancer has not spread far but is too large for immediate surgery will receive the com…

This study looks at whether a 1-year treatment with two drugs (Enhertu and nivolumab) can safely prevent cancer from returning in people with HER2-positive esophageal or stomach-junction cancer. Participants have already completed standard therapy (chemoradiation and surgery) but…

This study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can help shrink tumors in people with esophageal or gastroesophageal junction cancer before surgery. About 278 adults with stage II to IVA cancer will be e…

This study tests a simple, less invasive screening tool—a sponge on a string—to detect Barrett's esophagus and esophageal cancer. Researchers aim to see if DNA markers from the sponge sample can accurately identify high-grade dysplasia and cancer. About 450 adults with Barrett's …

This study explores whether a device called Endosign, which collects tissue samples from the mouth, can reliably monitor Barrett's esophagus—a condition that can lead to esophageal cancer. Current monitoring requires regular endoscopies, which are uncomfortable and costly. The st…

This phase 2 trial tests whether taking aspirin can prevent Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. About 21 participants will take either aspirin or a placebo for 12 months. Researchers will measure specific protein…